Eiger BioPharmaceuticals, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019
Revenue
Product revenue, net
Other revenue
Total revenue
Costs and operating expenses:
Cost of sales
Research and development
Selling, general and administrative
Total costs and operating expenses
Loss from operations
Interest expense
Interest income
Other (expense) income, net
Loss before provision for income taxes
Provision for income taxes
Net loss
Net loss per common share, basic and diluted
Weighted-average common shares outstanding, basic and diluted
Net loss per common share:
Basic (in USD per share)
Diluted (in USD per share)
Weighted-average common shares outstanding:
Basic (in shares)
Diluted (in shares)

Comments